SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Dreyling Martin)
 

Search: WFRF:(Dreyling Martin) > Health-related qual...

Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus

Hess, Georg (author)
Johannes-Gutenberg University Mainz
Rule, Simon (author)
Plymouth University
Jurczak, Wojciech (author)
Jagiellonian University
show more...
Jerkeman, Mats (author)
Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital
Santucci Silva, Rodrigo (author)
Instituto de Ensino e Pesquisa do Hospital São Lucas
Rusconi, Chiara (author)
Niguarda Hospital
Caballero, Dolores (author)
University Hospital of Salamanca
Joao, Cristina (author)
Champalimaud Foundation
Witzens-Harig, Mathias (author)
University Hospital Heidelberg
Bence-Bruckler, Isabelle (author)
Cho, Seok-Goo (author)
Zhou, Wenjiong (author)
Janssen Pharmaceuticals, US
Goldberg, Jenna D (author)
Janssen Pharmaceuticals, US
Trambitas, Cristina (author)
Janssen Inc., Canada
Enny, Christopher (author)
Janssen Pharmaceuticals, US
Vermeulen, Jessica (author)
Janssen Pharmaceuticals, US
Traina, Shana (author)
Janssen Pharmaceuticals, US
Chiou, Chiun Fang (author)
Janssen Pharmaceuticals, US
Diels, Joris (author)
Janssen Pharmaceutica
Dreyling, Martin (author)
University Hospital Munich
show less...
 (creator_code:org_t)
2017-05-30
2017
English.
In: Leukemia and Lymphoma. - : Informa UK Limited. - 1042-8194 .- 1029-2403. ; 58:12, s. 2824-2832
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Mantle cell lymphoma (MCL) is a rare, aggressive, incurable B-cell malignancy. Ibrutinib has been shown to be highly active for patients with relapsed/refractory (R/R) MCL. The RAY trial (MCL3001) was a phase 3, randomized, open-label, multicenter study that compared ibrutinib with temsirolimus in patients with R/R MCL. Active disease is frequently associated with impaired functional status and reduced well-being. Therefore, the current study employed two patient-reported outcome instruments, the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and the EQ-5D-5L, to assess symptoms, well-being, health status, and health-related quality of life of patients on treatment within the RAY trial. We found that patients on ibrutinib had substantial improvement in FACT-Lym subscale and total scores, and had improvement in EQ-5D-5L utility and VAS scores compared with temsirolimus patients, indicating a superior well-being. These improvements in well-being correlated with clinical response, indicating that better health-related quality of life was associated with decreased disease burden.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Keyword

Bruton’s tyrosine kinase inhibitor
EQ-5D-5L
FACT-Lym
ibrutinib
mantle cell lymphoma
patient-reported outcomes

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view